null

null

null

null

null

null

null

null

null

Minimal debt; Allogene operates near-debt-free with ~$400M+ cash runway; 20bp rate rise has negligible P&L impact

Low sensitivity; cash-burning biotech with no significant floating-rate debt; higher rates modestly reduce investment income yield

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) CAR-T cell manufacturing reagents (Thermo Fisher/Lonza); 2) allogeneic T-cell donor procurement concentrated in US/EU donors

Minimal international revenue; primarily US clinical-stage; negligible sovereign currency devaluation exposure currently

Operations concentrated in South San Francisco, CA; EU clinical trial sites; no material international commercial revenue generating FX risk

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; Thermo Fisher and Lonza provide critical allogeneic cell manufacturing inputs; switching cost is 12–24 months and regulatory re-validation

Clinical-stage biopharmaceutical; cloud disruption would impair data/trial management but not core manufacturing or cell therapy operations

R&D and manufacturing operationally grounded; 30-day cloud termination would require 60–90 day recovery for informatics and trial data systems

Moderate API coupling risk; relies on clinical data platforms (Medidata/Veeva); switching feasible but costly at 6–12 months disruption

Not applicable; revenue model is grant/partnership/licensing-based, not a securities offering; Howey Test risk is null

Very High

Moderate; EU clinical trial patient data subject to GDPR; US patient data under HIPAA/CCPA; compliance frameworks in place but audit risk remains

Low; niche allogeneic CAR-T space with limited market share; no dominant pricing position; no current antitrust scrutiny identified

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% non-recurring; revenue from collaboration agreements (Pfizer partnership) and grants; no subscription or retainer revenue stream

Milestone and royalty payments from Pfizer collaboration; potential future product sales upon regulatory approval; entirely partnership-driven currently

No commercial product pricing yet; future pricing expected in CAR-T premium tier ($400K–$600K per patient course, comparable to Kymriah/Yescarta)

High potential pricing power post-approval; allogeneic off-the-shelf model could command premium over autologous if efficacy is demonstrated

Target gross margin 60–75% at commercial scale; near-term margins negative due to clinical manufacturing overhead and no product revenue

No free-rider risk; proprietary allogeneic platform; IP-protected; clinical partners contractually bound; not applicable in SaaS sense

Headcount-linear currently; R&D-intensive stage requires proportional scientific staff growth; manufacturing scale could become sublinear at commercial phase

High marginal cost in clinical phase; transitioning to commercial would require GMP manufacturing scale-up with significant capex before margin leverage

Not applicable; Allogene is not a franchise business model

At 10x scale (commercial launch), CAC would shift to hospital/payer contracting; patient acquisition cost estimated $50K–$150K via oncology channel

No traditional network effects; proprietary TALEN gene-editing platform creates durable IP moat but not demand-side network effects

-45.9% Return on Assets (Negative equity)

Moderate-high resilience; oncology treatments are medically necessary; payer coverage and clinical demand relatively inelastic to economic cycles

Biopharmaceutical partners (Pfizer as primary collaborator); reliance on single partner represents significant concentration risk

Future commercial customers: oncology treatment centers, hospital systems, and payers; currently pre-revenue in this segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital being allocated to future-state GMP cell therapy manufacturing infrastructure; legacy operations minimal; forward-looking capex deployment

0001737287

ALLO